Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use

  • Van den Bergh J
  • Smits E
  • Versteven M
  • et al.
Citations of this article
Mendeley users who have this article in their library.


Personalized dendritic cell- (DC-) based vaccination has proven to be safe and effective as second-line therapy against various cancer types. In terms of overall survival, there is still room for improvement of DC-based therapies, including the development of more immunostimulatory DC vaccines. In this context, we redesigned our currently clinically used DC vaccine generation protocol to enable transpresentation of interleukin- (IL-) 15 to IL-15R βγ -expressing cells aiming at boosting the antitumor immune response. In this study, we demonstrate that upon electroporation with both IL-15 and IL-15Rα -encoding messenger RNA, mature DC become highly positive for surface IL-15, without influencing the expression of prototypic mature DC markers and with preservation of their cytokine-producing capacity and their migratory profile. Functionally, we show that IL-15-transpresenting DC are equal if not better inducers of T-cell proliferation and are superior in tumor antigen-specific T-cell activation compared with DC without IL-15 conditioning. In view of the clinical use of DC vaccines, we evidence with a time- and cost-effective manner that clinical grade DC can be safely engineered to transpresent IL-15, hereby gaining the ability to transfer the immune-stimulating IL-15 signal towards antitumor immune effector cells.




Van den Bergh, J. M. J., Smits, E. L. J. M., Versteven, M., De Reu, H., Berneman, Z. N., Van Tendeloo, V. F. I., & Lion, E. (2017). Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use. Journal of Immunology Research, 2017, 1–8.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free